Given that DUSP1 inhibition may worsen underlying autoimmune conditions and neurological disorders, when developing clinical trials, it must be noted that cancer patients with these comorbidities may not be ideal candidates for DUSP1 targeting. The gene discussed is DUSP1; the disease is cancer.